GSK2878175
non-nucleoside nonstructural 5B protein (NS5B)-palm polymerase inhibitor
Also Known As:
6-((7-Chloro-1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)(methylsulfonyl)amino)-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide
Networked: 2
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Banyai, Tivadar:
1 article
(01/2020)
|
| 2. | Campbell, Fiona:
1 article
(01/2020)
|
| 3. | Chen, Shuguang:
1 article
(01/2020)
|
| 4. | Dalekos, George N:
1 article
(01/2020)
|
| 5. | Deeg, Mark:
1 article
(01/2020)
|
| 6. | Deng, Yanli:
1 article
(01/2020)
|
| 7. | Goulis, Ioannis:
1 article
(01/2020)
|
| 8. | Hamatake, Robert:
1 article
(01/2020)
|
| 9. | Han, Kelong:
1 article
(01/2020)
|
| 10. | Horvath, Gabor:
1 article
(01/2020)
|
Related Diseases
| 1. | Chronic Hepatitis C
01/01/2018
- " GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naïve chronic hepatitis C subjects." 01/01/2020
- " Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants." 01/01/2020
- " In conclusion, single injection of RG-101 combined with 12 weeks of GSK2878175 oral tablets was generally well tolerated and resulted in high SVR rates in chronic hepatitis C patients. " 01/01/2018
- " GSK2878175 is a potent, pan-genotypic, non-nucleoside, nonstructural protein 5B palm polymerase inhibitor being developed for the treatment of chronic hepatitis C (CHC). " 01/01/2020
- " In a randomized, open-label, Phase 2 study (RG101-04), investigators enrolled 26 adult chronic hepatitis C patients to evaluate safety and efficacy of single subcutaneous injection of RG-101 (4 mg/kg) and daily oral tablets of GSK2878175 (20 mg) for 6, 9 or 12 weeks. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures